Holen Sie sich die Stockscreener-App
3.1281
0.58%
0.0181
Schlusskurs vom Vortag:
$3.11
Offen:
$3.15
24-Stunden-Volumen:
5,733
Relative Volume:
0.38
Marktkapitalisierung:
$435.28M
Einnahmen:
$16.82M
Nettoeinkommen (Verlust:
$-112.19M
KGV:
-1.4101
EPS:
-2.2183
Netto-Cashflow:
$-91.84M
1W Leistung:
-7.18%
1M Leistung:
-18.33%
6M Leistung:
+19.62%
1J Leistung:
-15.91%
1-Tages-Spanne:
$3.11
$3.2999
1-Wochen-Bereich:
$3.03
$3.36
52-Wochen-Spanne:
$1.53
$4.05
Inventiva Adr Stock (IVA) Company Profile
Vergleichen Sie IVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
3.1281 | 468.56M | 16.82M | -112.19M | -91.84M | -2.2183 |
|
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-21 | Eingeleitet | TD Cowen | Buy |
| 2024-11-12 | Eingeleitet | UBS | Neutral |
| 2023-10-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-19 | Hochstufung | Societe Generale | Sell → Buy |
| 2023-03-17 | Eingeleitet | Stifel | Buy |
| 2022-11-15 | Herabstufung | Societe Generale | Buy → Sell |
| 2021-03-08 | Herabstufung | Societe Generale | Buy → Sell |
| 2020-08-05 | Eingeleitet | ROTH Capital | Buy |
| 2020-08-04 | Eingeleitet | Guggenheim | Buy |
| 2020-08-04 | Eingeleitet | Stifel | Buy |
Alle ansehen
Inventiva Adr Aktie (IVA) Neueste Nachrichten
Inventiva publie ses informations financières¹ du 1er trimestre 2025 - GlobeNewswire Inc.
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Inventiva achieves milestone with Phase 3 study enrollment, says H.C. Wainwright - TipRanks
Stifel maintains Buy on Inventiva shares with $17 target - Investing.com
Inventiva SA ADR Reports 2024 Financial Results and Strategic Updates - TipRanks
Inventiva earnings missed by $0.03, revenue topped estimates - Investing.com
Top 10 Best Indian Companies In Smart Grids Solutions 2025 - Inventiva
Stifel reiterates Buy rating on Inventiva stock, cites financing deal - Investing.com
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Why Are Criminals Still in Power? 151 Lawmakers with Charges of Crimes Against Women Continue to Hold Office! Is This the End of Integrity in Indian Politics? - inventiva.co.in
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA) - Nasdaq
NOTA, No Votes and Unopposed Nominations: The Grey Areas of the Indian Election Process Explained - inventiva.co.in
symbol__ Stock Quote Price and Forecast - CNN
Supreme Court To Hear Plea Against Electoral Bonds From October 31 - Inventiva
Top 10 Best Handicraft Companies In USA 2023 - inventiva.co.in
Top 20 Best Hardware & Networking Company In India 2023 - inventiva.co.in
Inventiva SaAdr Share Price Today (NASDAQ: IVA)Inventiva SaAdr Stock Price Live Quote - INDmoney
The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study - Yahoo Finance
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Finanzdaten der Inventiva Adr-Aktie (IVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
6.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):